New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 9, 2012
08:41 EDTIPXL, AVNRAvanir sues Impax over planned Nuedexta generic, Bloomberg reports
Avanir Pharmaceuticals (AVNR) is suing Impax Laboratories (IPXL) for allegedly infringing a new patent for the drug Nuedexta and planning to market a generic version of the drug before the patent expires in 2023, reported Bloomberg, citing a complaint filed in a federal court in Delaware. Reference Link
News For AVNR;IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
07:36 EDTIPXLImpax receives tentative FDA approval for generic Vytorin ANDA
Impax Laboratories announced that Impax has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for the generic version of the ezetimibe and simvastatin containing tablets, in 10 mg / 10 mg, 10 mg / 20 mg, 10 mg / 40 mg and 10 mg / 80 mg strengths. "We are pleased to receive tentative approval from the FDA for our generic version of Vytorin tablets," said Fred Wilkinson, President and CEO. "We will continue to work with the FDA to gain final approval upon the expiration of the U.S. patents and associated pediatric exclusivity on April 25, 2017, and are currently planning to be among the first generic products to market."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use